Delving into the Latest Updates on Iodofiltic acid I-123 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug, Diagnostic radiopharmaceuticals

Synonyms

15-(4-Iodophenyl)-3(R,S)-Methylpentadecanoic Acid (123I), IPPA, Iodofiltic Acid I 123

+ [4]

Target-

Mechanism

SPECT(Single-photon emission-computed tomography enhancers)

Therapeutic Areas

Other Diseases

Active Indication

Diagnostic agents

Inactive Indication

Coronary Artery Disease

Originator Organization

Pfizer Inc.

Active Organization

Nihon Medi-Physics Co., Ltd.

Inactive Organization

Pfizer Inc.

Drug Highest PhaseApproved

First Approval Date

JP (19 Jan 1993),

Diagnostic agents

Regulation-

Login to view timeline

Structure

Molecular FormulaC22H35IO2

InChIKeyNPCIWINHUDIWAV-NSYCNWAXSA-N

CAS Registry123748-56-1

This is an open-label phase 2 study recruiting low, moderate, and high likelihood ACS patients from approximately 60 centers. Patients will be imaged with iodofiltic acid I 123 for the detection of myocardial ischemia. Readers independent of the clinical study centers will review results of imaging studies in a blinded fashion at an imaging core lab. The resulting independent reading of the images will be compared against the truth standard for ACS.

Start Date01 May 2007

Sponsor / Collaborator

Molecular Insight Pharmaceuticals, Inc.

100 Clinical Results associated with Iodofiltic acid I-123

Login to view more data

100 Translational Medicine associated with Iodofiltic acid I-123

Login to view more data

100 Patents (Medical) associated with Iodofiltic acid I-123

Login to view more data

164

Literatures (Medical) associated with Iodofiltic acid I-123

01 Jan 2024·Annals of Nuclear Medicine

Correction: Practice recommendation for measuring washout rates in 123I-BMIPP fatty acid images

Author: Kawahito, Michitomo ; Nakajima, Kenichi ; Miyauchi, Hideyuki ; Kudo, Takashi ; Fujimoto, Shinichiro ; Iimori, Takashi ; Hirano, Ken-Ichi

01 Jan 2024·Annals of Nuclear Medicine

Practice recommendation for measuring washout rates in 123I-BMIPP fatty acid images

Article

Author: Kawahito, Michitomo ; Nakajima, Kenichi ; Miyauchi, Hideyuki ; Kudo, Takashi ; Fujimoto, Shinichiro ; Iimori, Takashi ; Hirano, Ken-Ichi

AbstractThe purpose of this practice recommendation is to specifically identify the critical steps involved in performing and interpreting 123I-β-methyl-iodophenyl-pentadecanoic acid (BMIPP) single-photon emission computed tomography (SPECT) and measurement of washout rate (WR) from the heart. This document will cover backgrounds, patient preparation, testing procedure, visual image interpretation, quantitation methods using planar and SPECT studies, and reporting of WR. The pitfall and some tips for the calculation of 123I-BMIPP WR are also included. The targets of global and regional WR calculation include ischemic heart disease, cardiomyopathy, heart failure, and triglyceride deposit cardiomyovasculopathy, an emerging rare heart disease.

01 Nov 2022·Journal of Interpersonal ViolenceQ2 · PSYCHOLOGY

Exploring Insecure Romantic Attachment and Justifications for the Use of Intimate Partner Psychological Aggression in Couples

Q2 · PSYCHOLOGY

Article

Author: Brassard, Audrey ; Lafontaine, Marie-France ; Péloquin, Katherine ; Leclerc, Marie-Eve

The attachment theory has commonly been used to examine intimate partner psychological aggression (IPPA), but few studies have examined its association with self-reported justifications for one’s own use of IPPA. Behaviors, including the use of IPPA, are influenced, maintained, and function within the context of their justifications, highlighting the importance of investigating these justifications to obtain a clearer picture of IPPA. This study examined whether insecure romantic attachment (i.e., attachment anxiety and attachment avoidance) in both partners of a couple was associated with their justifications for their own use of IPPA. A community sample of 81 mixed-sex couples who reported using IPPA in the last year completed self-reported questionnaires on adult romantic attachment and their justifications for their use of IPPA. Results of a path analysis based on the actor-partner interdependence model revealed moderate positive associations between attachment anxiety and one’s use of internal and external justifications for their IPPA perpetration in men and women. An unexpected dyadic positive association is discussed. These results suggest that the use of justifications for one’s use of IPPA may reflect a strategy of hyperactivation that could contribute to the cycle of psychological aggression. Uncovering the function of these justifications could provide important therapeutic benefits, which are discussed in the study’s implications.

100 Deals associated with Iodofiltic acid I-123

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB05683

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diagnostic agents	JP	Nihon Medi-Physics Co., Ltd.	19 Jan 1993

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Coronary Artery Disease	Phase 3	-	Pfizer Inc.	-
Diagnostic agents	Phase 3	-	Pfizer Inc.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00514501 (Zeus-ACS, CTgov)	Phase 2	Acute Coronary Syndrome	510	Iodofiltic acid I 123	jgrrzooxdp(zmzhvejatv) = suihnrqrzl jchbmmnvqx (eguztdoulh, zsghmgsupa - bxqtmgewxe) View more	-	25 Jan 2016
NCT00514501 (Zeus-ACS, Pubmed \| J Am Coll Cardiol)	Phase 2	Acute Coronary Syndrome	507	Iodofiltic acid I 123 (BMIPP) (BMIPP)	(udbfqhpuet) = ezekocvqos hvupkdbxdr (lmilxqflqn ) View more	-	20 Jul 2010